A company insider recently sold 23,229 shares of Ironwood Pharmaceuticals Inc. [IRWD]. Should You Sale?

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Ironwood Pharmaceuticals Inc. shares valued at $263,649 were sold by MCCOURT Thomas A on Aug 01. At $11.35 per share, MCCOURT Thomas A sold 23,229 shares. The insider’s holdings dropped to 757,785 shares worth approximately $8.7 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, MCCOURT Thomas A sold 19,959 shares, netting a total of over 231,125 in proceeds. Following the sale of shares at $11.58 each, the insider now holds 778,922 shares.

Before that, Kessler Marla L had sold 7,610 shares from its account. In a trade valued at $88,656, the Director traded Ironwood Pharmaceuticals Inc. shares for $11.65 each. Upon closing the transaction, the insider’s holdings decreased to 7,610 shares, worth approximately $0.97 million.

As published in their initiating research note from Piper Sandler on April 22, 2022, Ironwood Pharmaceuticals Inc. [IRWD] has been an Overweight and the price target has been revised to $16. This represents a 28.25% premium over Thursday’s closing price. Analysts at Wells Fargo downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal weight”‘ outlook in a report released in late September. As of June 17, 2020, Northland Capital has initiated its “an Outperform” rating for IRWD.

Analyzing IRWD’s Price Performance

On Thursday, Ironwood Pharmaceuticals Inc. [NASDAQ: IRWD] rose 2.41% to $11.48. The stock’s lowest price that day was $10.94, but it reached a high of $11.52 in the same session. During the last five days, there has been a drop of approximately -7.27%. Over the course of the year, Ironwood Pharmaceuticals Inc. shares have dropped approximately -1.54%. Shares of the company reached a 52-week high of $12.95 on 03/30/22 and a 52-week low of $10.13 on 02/17/22. A 50-day SMA is recorded $11.61, while a 200-day SMA reached $11.73. Nevertheless, trading volume fell to 2.56 million shares from 5.24 million shares the previous day.

Support And Resistance Levels for Ironwood Pharmaceuticals Inc. (IRWD)

According to the 24-hour chart, there is a support level at 11.11, which, if violated, would cause prices to drop to 10.73. In the upper region, resistance lies at 11.69. The next price resistance is at 11.89. RSI (Relative Strength Index) is 47.39 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.49, which suggests the price will decrease in the coming days. Percent R is at 59.06%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Ironwood Pharmaceuticals Inc. subject to short interest?

Stocks of Ironwood Pharmaceuticals Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 3.43 million shares to 17.51 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 14.08 million shares. A jump of 19.59% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.96 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.96.

Which companies own the most shares of Ironwood Pharmaceuticals Inc. (IRWD)?

According to Sarissa Capital Management LP filings, the company currently owns 16,390,000 shares, which is about 10.65% of the total IRWD shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 16390000.0 shares. With the completion of the sale transaction, Wellington Management Co. LLP’s stake is now worth $175,044,390. Brown Capital Management LLC reduced a -12.48% interest valued at $164.06 million while The Vanguard Group, Inc. sold a -139,746 stake. A total of 26,823 shares of Ironwood Pharmaceuticals Inc. were sold by BlackRock Fund Advisors during the quarter, and 388,742 were bought by Westfield Capital Management Co. In its current portfolio, SSgA Funds Management, Inc. holds 8,297,067 shares valued at $95.67 million.

In terms of Ironwood Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $12.50 in the next 12 months, up nearly 11.51% from the previous closing price of $11.21. Analysts anticipate Ironwood Pharmaceuticals Inc. stock to reach $16.00 by 2022, with the lowest price target being $9.00. In spite of this, 4 analysts ranked Ironwood Pharmaceuticals Inc. stock as a Hold at the end of 2022.


Please enter your comment!
Please enter your name here